These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 36470258)

  • 1. Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib + Checkpoint Inhibitor.
    Zakharia Y; Huynh L; Du S; Chang R; Pi S; Sundaresan S; Duh MS; Zanotti G; Thomaidou D
    Clin Genitourin Cancer; 2023 Oct; 21(5):e343-e351. PubMed ID: 37087399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment.
    Minami K; Osawa T; Kojima T; Hara T; Eto M; Takeuchi A; Nakai Y; Ueda K; Ozawa M; Uemura M; Ohba K; Tamura K; Shindo T; Nakagomi H; Takahashi A; Anai S; Yokomizo A; Morizane S; Kimura T; Shimazui T; Miyauchi Y; Mitsuzuka K; Hara H; Yoshimura K; Shiina H; Ito YM; Murai S; Nishiyama H; Shinohara N; Kitamura H;
    Urol Oncol; 2023 Nov; 41(11):458.e9-458.e19. PubMed ID: 37798145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England.
    Brown J; Harrow B; Marciniak A; McCarthy C; Houchard A; Cirneanu L; Protheroe A
    Drugs Real World Outcomes; 2024 Jun; 11(2):195-207. PubMed ID: 38265633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan.
    Harada KI; Sato R; Bando Y; Sano A; Matsushita Y; Tamura K; Terakawa T; Furukawa J; Fujimoto N; Fujisawa M; Miyake H
    Int J Urol; 2023 Sep; 30(9):772-777. PubMed ID: 37345413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.
    Tomita Y; Fukasawa S; Oya M; Uemura H; Shinohara N; Habuchi T; Rini BI; Chen Y; Bair AH; Ozono S; Naito S; Akaza H
    Jpn J Clin Oncol; 2016 Nov; 46(11):1031-1041. PubMed ID: 27572087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axitinib after Treatment Failure with Sunitinib or Cytokines in Advanced Renal Cell Carcinoma-Systematic Literature Review of Clinical and Real-World Evidence.
    Sharma A; Bahl A; Frazer R; Godhania E; Halfpenny N; Hartl K; Heldt D; McGrane J; Şahbaz Gülser S; Venugopal B; Ritchie A; Crichton K
    Cancers (Basel); 2024 Jul; 16(15):. PubMed ID: 39123435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial Comment to Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan.
    Kondo T
    Int J Urol; 2023 Sep; 30(9):777-778. PubMed ID: 37452557
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and toxicity of axitinib and sorafenib monotherapy for patients with renal cell carcinoma: a meta-analysis.
    Qin F; Yu H; Bai J
    J Biomed Res; 2017 Nov; ():. PubMed ID: 29277834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated recommendation on molecular-targeted therapy for metastatic renal cell cancer.
    Hoshi S; Numahata K; Kanno H; Sato M; Kuromoto A; Nezu K; Sakai T; Konno C; Ishizuka Y; Izumi H; Taguchi K; Ono K; Hoshi K; Kanto S; Takahashi R; Vladimir B; Akimoto N; Sasagawa I; Ohta S
    Mol Clin Oncol; 2017 Oct; 7(4):591-594. PubMed ID: 29046793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma.
    Shafrin J; Sullivan J; Chou JW; Neely MN; Doan JF; Maclean JR
    Cancer Manag Res; 2017; 9():731-739. PubMed ID: 29238223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete response of metastatic RCC with caval vein thrombus following treatment with pembrolizumab and axitinib: is it possible to extend the indications for systemic therapy?
    Grosso AA; DI Maida F; Mari A; Raspollini MR; Antonuzzo L; Minervini A
    Minerva Urol Nephrol; 2024 Jun; 76(3):382-384. PubMed ID: 38618704
    [No Abstract]   [Full Text] [Related]  

  • 12. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
    Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI
    Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets.
    MacLean E; Cisar L; Mehle K; Eremina D; Quigley JM
    J Manag Care Spec Pharm; 2016 Jun; 22(6):723-732u. PubMed ID: 27231799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Axitinib: a review in advanced renal cell carcinoma.
    Keating GM
    Drugs; 2015 Nov; 75(16):1903-13. PubMed ID: 26487541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy.
    Shin SJ; Lee JL; Kwon TG; Shim BY; Chung HS; Kim SH; Park SH
    Cancer Res Treat; 2023 Apr; 55(2):643-651. PubMed ID: 36470258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use.
    Tzogani K; Skibeli V; Westgaard I; Dalhus M; Thoresen H; Slot KB; Damkier P; Hofland K; Borregaard J; Ersbøll J; Salmonson T; Pieters R; Sylvester R; Mickisch G; Bergh J; Pignatti F
    Oncologist; 2015 Feb; 20(2):196-201. PubMed ID: 25616431
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.